CorPath System to Be Featured for Complex Interventions At SDCI 2016: San Diego Cardiovascular Interventions Course

Thursday, June 30, 2016

WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that its CorPath® System will be highlighted in several presentations on new therapies and techniques for the treatment of high-risk patients with complex cardiovascular disease at SDCI 2016: San Diego Cardiovascular Interventions Course, July 8 and 9, at the Estancia La Jolla Hotel & Spa, La Jolla, CA. Corindus' CorPath System, the first FDA-cleared medical device to bring robotically-assisted precision to radial, coronary and peripheral procedures, will be featured in two live robotic-assisted complex percutaneous coronary interventions (PCIs) during the course.

"Robotic therapy has transformed the way we perform interventional procedures today. The benefits of robotics for staff and patients will continue to grow as technology evolves, and we are excited to be at the forefront of this growth," said Course Director Ehtisham Mahmud, MD, FACC, FSCAI, Division Chief, Cardiovascular Medicine and Medical Director, Sulpizio Cardiovascular Center at the University of California, San Diego. "This course seeks to highlight the value and applicability of robotic therapy in conjunction with other emerging technologies in the cath lab to treat complex disease."

The SDCI 2016 course will highlight how robotic therapy can enhance physician and staff safety when used in complex and high-risk PCI procedures. A particular focus will be the integration of robotic therapy in procedures that also leverage the capabilities of other advanced therapeutic tools.

"The SDCI meeting is a great opportunity to advance the science of robotic therapy through demonstrations of unique live cases and presentations on the most recent clinical data for complex robotic PCI," said Corindus President and CEO Mark Toland. "As awareness of occupational hazards in the cath lab continues to grow, our CorPath technology will play a key role in building the cath lab of the future."

For additional information on SDCI 2016: San Diego Cardiovascular Interventions Course, visit

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic-assisted precision to radial, coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements that:

  • the benefits of robotics for staff and patients will continue to grow as technology evolves and
  • as awareness of occupational hazards in the cath lab continues to grow, CorPath technology will play a key role in building the cath lab of the future.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at